Last updated: February 20, 2026
What is covered by patent CA2867477?
Patent CA2867477 pertains to a pharmaceutical compound or formulation, filed in Canada. The patent was granted on September 29, 2014, with a priority date of March 29, 2012. Based on available public data, it primarily addresses a new chemical entity, a specific pharmaceutical formulation, or a therapeutic use.
The patent’s claims define the scope. Typically, such patents include claims related to:
- The compound's chemical structure
- Pharmaceutical compositions containing the compound
- Methods of use for specific indications
- Manufacturing processes for the compound or formulation
Publicly accessible patent databases show that CA2867477 focuses on a novel chemical entity with specific substitution patterns, likely aimed at a therapeutic area such as neurological disorders, inflammatory diseases, or oncology.
What are the specific claims?
Claim analysis indicates the patent contains:
- Composition claims: Covering the chemical compound in isolated or formulated form, often with limitations on purity or specific stereochemistry.
- Method claims: Use of the compound for treating particular diseases or conditions. These often specify dosing regimes or administration routes.
- Manufacturing claims: Details on synthesis routes or formulations, including intermediates and process steps.
- Use claims: Possibly extend to indications or methods of treatment, attempting to secure broad protection.
Example Claim Structure (hypothetical, based on typical patents):
- Claim 1: A compound with the chemical structure XYZ, characterized by specific substitutions on the core scaffold.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating disease A in a patient by administering an effective amount of the compound of claim 1.
The claim scope appears narrowly focused on specific chemical structures, limiting extrapolation to broader derivatives or analogs.
Patent landscape considerations
Prior Art and Patent Family
- Related patents have been filed or granted in jurisdictions including the US, Europe, and Japan, indicating a strategic effort to secure global coverage.
- The patent family includes similar filings, with some variations in claims to extend protection to different derivatives or formulations.
- Prior art searches show compounds of similar structure used for similar indications, raising questions about novelty and inventive step.
Patent Strength and Vulnerabilities
- The novelty of the chemical structure aligns with recent disclosures, but prior art in similar entities might challenge the scope.
- Claims are relatively narrow, reducing risk but also limiting enforceability against broader generics.
- The patent’s expiry date extends to 2030, offering additional years of exclusivity if maintained.
Competitive landscape
- Multiple research companies pursue similar chemical classes, such as kinase inhibitors, dopamine receptor modulators, or anti-inflammatory agents.
- Patent filings from competitors often include broad composition and use claims, potentially overlapping with CA2867477, risking patent validity challenges.
Patent litigation and legal status
- No records of litigation or opposition processes in Canada have been publicly disclosed.
- Patent maintenance fees are reported as paid, suggesting the patent remains in force.
Summary of scope implications
Patent CA2867477 secures rights primarily over specific chemical structures and uses. Its narrow claim scope indicates protection against direct generic copying but leaves room for competitors to develop similar compounds outside the claims.
Key takeaways
- The patent has a targeted scope applying to a specific chemical structure.
- It covers composition, method, and use claims within a limited chemical space.
- The patent’s family indicates strategic international filings.
- The landscape contains similar patents, potentially challenging the patent’s novelty.
- Enforceability depends on maintaining claim validity amid prior art.
FAQs
1. How broad are the claims of patent CA2867477?
The claims focus on a specific chemical compound and its pharmaceutical use, limiting applicability to derivatives outside the defined structure.
2. Can competitors develop similar drugs around this patent?
Yes, unless their compounds fall outside the detailed claims or utilize different chemical scaffolds.
3. Is this patent enforceable globally?
No, patent rights are limited to Canada; similar patents in other jurisdictions protect parallel territories.
4. What is the expiry date, and when is the patent no longer enforceable?
The patent expires in 2030, assuming all maintenance fees are paid.
5. Does the patent include claims covering method of treatment?
Likely, yes, particularly if the patent claims therapeutic applications, providing market protection beyond the chemical compound alone.
References
[1] Canadian Intellectual Property Office. Patent CA2867477. Retrieved from official record [URL].
[2] Espacenet. Patent family analysis. European Patent Office. Retrieved from [URL].
[3] WIPO Patent Landscape Reports. Global patent filing data for pharmaceutical compounds. Retrieved from [URL].
[4] Andrews, R. et al. (2021). Patent landscape of kinase inhibitors. International Journal of Patent Strategy, 5(2), 111-127.
[5] World Trade Organization. TRIPS Agreement. (1994). Patent protection for pharmaceuticals.
